Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 3/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040964 | 0.81 | CRBN (1.00) | CRBNDDB1ALDH1A1MEN1KMT2A | |
| SCHEMBL31040968 | 0.81 | DDB1 (0.68) | CRBNDDB1ALDH1A1TNKSTNKS2 | |
| SCHEMBL31040952 | 0.81 | CRBN (1.00) | CRBNDDB1ALDH1A1MEN1KMT2A | |
| SCHEMBL31040960 | 0.79 | DDB1 (0.65) | CRBNDDB1ALDH1A1MEN1KMT2A | |
| SCHEMBL31040967 | 0.79 | DDB1 (0.65) | CRBNDDB1ALDH1A1MEN1KMT2A | |
| SCHEMBL30257675 | 0.78 | DDB1 (0.64) | CRBNDDB1MEN1KMT2AHSD17B10 | |
| SCHEMBL31040950 | 0.77 | DDB1 (0.62) | CRBNDDB1 | |
| SCHEMBL30257619 | 0.77 | DDB1 (0.62) | CRBNDDB1MEN1KMT2A | |
| SCHEMBL31040975 | 0.74 | CRBN (0.59) | CRBNDDB1TNKSTNKS2 | |
| SCHEMBL26683769 | 0.73 | DDB1 (0.57) | CRBNDDB1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRBN, CUL1, CUL5 | CRBN 1/4885DDB1 188/4885ALDH1A1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.